Ivonescimab (VEGF/PD1 bispecific) shows response rates of 65% in IMDC good risk RCC #ESMO26

Single agent VEGF TKI is probably close to this activity, but it’s higher than single agent PD1

It’s likely combinations will be needed to clearly improve on existing 1st line options @OncoAlert @DrChoueiri